Redirection of sphingolipid metabolism drives cytoskeletal defects in SPLIS and reveals ROCK inhibition as therapy

Journal:

Journal of Clinical Investigation

Published:

2026-04-23

DOI:

10.1172/jci194427

Affiliations:

4

Authors:

6

Go to article

Institutions	Authors	Share
University Hospital Zurich (UHZ), Switzerland	3.000000	0.50
University of California, San Francisco (UCSF), United States of America (USA)	2.000000	0.33
University Children's Hospital of Zurich, Switzerland	0.500000	0.08
University Hospital Tübingen (UKT), Uni Tübingen, Germany	0.500000	0.08

Interested in Medical Biochemistry and Metabolomics?